From the Center for Cell and Gene Therapy, Baylor College of Medicine; Houston Methodist Hospital; and Texas Children's Hospital, Houston, TX.
Cancer J. 2021;27(2):176-181. doi: 10.1097/PPO.0000000000000511.
Banked chimeric antigen receptor (CAR) T cells immediately available for off-the-shelf (OTS) application can solve key limitations of patient-specific CAR T-cell products while retaining their potency. The allogeneic nature of OTS cell therapies requires additional measures to minimize graft-versus-host disease and host-versus-graft immune rejection in immunocompetent recipients. In this review, we discuss engineering and manufacturing strategies aimed at minimizing unwanted interactions between allogeneic CAR T cells and the host. Overcoming these limitations will improve safety and antitumor potency of OTS CAR T cells and facilitate their wider use in cancer therapy.
现成的嵌合抗原受体 (CAR) T 细胞可立即用于现货 (OTS) 应用，可解决患者特异性 CAR T 细胞产品的关键限制，同时保持其效力。OTS 细胞疗法的同种异体性质需要额外的措施来最小化免疫功能正常的受者中的移植物抗宿主病和宿主抗移植物免疫排斥反应。在这篇综述中，我们讨论了旨在最小化同种异体 CAR T 细胞与宿主之间不必要相互作用的工程和制造策略。克服这些限制将提高 OTS CAR T 细胞的安全性和抗肿瘤效力，并促进它们在癌症治疗中的更广泛应用。
